PDF File - The Indian Society for Parasitology

Malaria vaccine development271987. Efficacy of murine malaria sporozoite vaccines: Herrera M. 2004. Use of long synthetic peptides to study theimplications for human vaccine development. Science 236: antigenicity and immunogenicity of the Plasmodium vivax453-456.circumsporozoite protein. Int J Parasitol 34: 1535-1546.Galinski MR, Corredor-Medina C, Povoa M, Crosby J,Ingravallo P and Barnwell JW. 1999. Plasmodium vivax Mzsurface protein-3 contains coiled-coilmotifs in an alaninerichcentral domain. Mol Biochem Parasitol 101: 131-147.Genton B and Corradin G. 2002. Malaria vaccines: from thelaboratory to the field Curr. Drug Targets ImmuneEndocrinol Metabol Disord 2: 255-267.Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D,Irving DO, Briggs WRS, Mai A, Ginny M, Adiguma T, RareL, Giddy A, Reberliske R, Stuerchler D and Alpers MP.2000. Safety and immunogenicity of a three-componentblood-stage malaria vaccine in adults living in an endemicarea of Papua New Guinea. Vaccine 18: 2504-2511.Golgi C. 1886. Sull infezione malarica. Arch Sci Med.,(Torino)10: 109-135.Good MF and Doolan DL. 1999. Immune effector mechanismsin malaria. Curr Opin Immunol 11:412-419.Grassi B and Feletti R. 1892. Contribuzione allo studio deiparassiti malarici. Atti Accad Gioenia Sci Nat Catania, 16:16-20.Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C,Hurtado S, Quintero G, Lopez JA, Corradin G and Arevalo-Hodder AN, Crewther PE and Anders RF. 2001. Specificity ofthe protective antibody response to apical membraneantigen 1. Infect Immun 69: 3286-3294.Galinski MR, Mengyao X and Barnwell JW. 2000.vivax reticulocyte binding protein-2 (Pv RBP-2) shares structural features with Pv RBP-1 and thePlasmodium yoelii 235 kDa rhoptry protein family. Mol.Biochem Parasitol 108: 257-262.Howard RF, Jacobson KC, Rickel E and Thurman J. 1998.Analysis of inhibitory epitopes in the Plasmodiumfalciparum rhoptry protein RAP-1 including identificationof a second inhibitory epitope. Infect Immun 66: 380-386.Howell SA, Withers-Martinez C, Kocken CH, Thomas AW andBlackman MJ. 2001. Proteolytic processing and primarystructure of Plasmodium falciparum apical membraneantigen-1 (Pf AMA-1). J Biol Chem 276: 31311-31320.Jones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR,Liang H, Haynes JD, Moch JK, Lucas C, Luu T, Magill AJ,Hoffman SL and Sim BKL. 2001. Protection of Aotusmonkeys by Plasmodium falciparum EBA-175 region IIDNA prime-protein boost immunization regimen. J InfectDis 183: 303-312.Kaslow DC and Shiloach J. 1994. Production, purification andimmunogenicity of a malaria transmission blockingvaccine candidate: TBV 25H expressed in yeast and purifiedusing nickel-NTA agarose. Biotechnology 12: 494-499.Kawabata Y, Udono H, Honma K, Ueda M, Mukae H, Kadota J,Kohno S and Yui K. 2002. Mz surface protein-1 specificimmune response is protective against exoerythrocyticfarms of Plasmodium yoelii. Infect Immun 70: 6075-6082.Kremsner PG, Winkler X, Wilding E, Prada J, Bienzle U,Graninger W and Nussler A. 1996. High plasma levels ofnitrogen oxides are associated with severe disease andcorrelate with rapid parasitological and clinical cure inPlasmodium falciparum malaria. Trans R Soc Trop MedHgy 90: 44-47.Locher CP, Tam LQ, Chang SP, McBride JS and Siddiqui WA.1996. Plasmodium falciparum: gp 195 tripeptide repeatspecificmonoclonal antibody inhibits parasite growth invitro. Exp Parasitol 84: 74-83.Grassi B, Bignami A and Bastianelli G. 1899a. Ciclo evolutivodelle semilune nell' Anopheles claviger. Atti. Soc. Studi.Malar 1: 14.Grassi B, Bignami A and Bastianelli G. 1899b. Resoconto deglistudi fatti sulla malaria durante il mese di Gennaio. Atti.Accad Naz Lencei Cl Sci Pis Nat Nat Rend 8: 100-104.Grun JL and Weidanz WP. 1981. Immunity to Plasmodiumchabaudi adami in the B-cell deficient mouse. Nature 290:143-145.Gruner AC, Brahimi K, Eling W, Konings R, Meis J, Aikawa M,Daubersies P, Guerin-Marchand C, Mellouk S, Snounou Gand Druilhe P. 2001. The Plasmodium falciparum knob-associated Pf EMP 3 antigen is also expressed at pre-erythrocytic stages and induces antibodies which inhibitsporozoite invasion. Mol Biochem Parasitol 112: 253-261.Herrera S, Bonelo A, Perlaza BL, Farnandez OL, Victoria L,Lenis AM, Soto L, Hurtado H, Acuna LM, Velez JD,Palacios R, Chen-Mok M, Corradin G and Arevalo-HerreraM. 2005. Safety and elicitation of humoral and cellularresponses in Colombian malaria-naive volunteers by aPlasmodium vivax circumsporozite protein derivedsynthetic vaccine. Am J Trop Med Hyg 73: 3-9.Lusingu JPA, Vestergaard LS, Alifrangis M, Mmbando BB,Theisen M, Kitua A, Lemnge MM and Theander TG. 2005.Cytophilic antibodies to Plasmodium falciparum glutamaterich protein are associated with malaria protection in an areaof holoendemic transmission. Malaria J 4: 48-55.MacMicking J, Xie QW and Nathan C. 1997. Nitric oxide andmacrophage function. Annu Rev Immunol 15: 323-350.Marshall VM, Tieqiao W and Coppel RL. 1998. Close linkageof three Mz surface protein genes on chromosome 2 ofPlasmodium falciparum. Mol Biochem Parasitol 94: 13-25.McConkey SJ, Reece WH, Moorthy VS, Webster D, DunachieS, Butcher G, Vuola JM, Blanchard TJ, Gothard P, WatkinsK, Hannan CM, Everaere S, Brown K, Kester KE,Cummings J, Williams J, Heppner DG, Pathan A, FlanaganK, Arulanantham N, Roberts MT, Roy M, Smith GL,